← Eichor
Condition: High Risk Of Recurrence Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: High Risk Of Recurrence

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R
Phase 2 · 4 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07239245Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07480941High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
Phase N/A · 1 location(s) · Clinica Universidad de Navarra, Universidad de Navarra · NCT06982469[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
EARLY_Phase 1 · 2 location(s) · Beijing Tiantan Hospital · NCT07655869Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention
NA · 1 location(s) · Johns Hopkins University · NCT059506595 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Phase 2 · 1 location(s) · Asan Medical Center · NCT05385549ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07270666Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
Phase 2 · 12 location(s) · Fundacion Clinic per a la Recerca Biomédica · NCT07018947Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07014150Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended En
Phase N/A · 12 location(s) · Shengjing Hospital · NCT04476485Endometrial Cancer Lymphadenectomy Trial
NA · 61 location(s) · Philipps University Marburg · NCT03438474A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
Phase 4 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06930573Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refra
EARLY_Phase 1 · 1 location(s) · Children's National Research Institute · NCT07017816A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in
Phase N/A · 284 location(s) · Novartis Pharmaceuticals · NCT06830720Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06454578Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 · 7 location(s) · AIDS Malignancy Consortium · NCT05077527Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05672251A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Phase 3 · 709 location(s) · AstraZeneca · NCT05774951MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Phase 1/Phase 2 · 3 location(s) · Ann & Robert H Lurie Children's Hospital of Chicago · NCT06712875RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer
Phase N/A · 1 location(s) · Fudan University · NCT06524167Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus H
Phase 2/Phase 3 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07366801Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT01371630Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 · 3 location(s) · M.D. Anderson Cancer Center · NCT03383575Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Canc
Phase 3 · 33 location(s) · M.D. Anderson Cancer Center · NCT03583710Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Inter
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05801913Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Inte
Phase 3 · 1 location(s) · Fujian Medical University Union Hospital · NCT06441110Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Phase 1/Phase 2 · 1 location(s) · Emory University · NCT04590664
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.